WHO advisers said Sanofi's Dengvaxia should only be used after a diagnostic confirms a prior infection. But fast and reliable tests don't exist.

​​​​​​​This is your brain on pharma ads. A neuroscience study from Conde Nast used brain sensors to measure brain reactions to digital pharma ads.

Just a few hours after Allergan confirmed that it was in buyout talks for hot target Shire, it said it didn’t intend to make an offer.

Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

AstraZeneca is looking to boost its key inhaler with two outcomes-based deals with regional insurers.

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.